Miller Steve's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Sep 15, 2022
- Accession no.
- 0001161697-22-000456
- Filed
- Sep 15, 2022
- Trade date
- Sep 13, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $1.82M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Miller SteveCIK 0001402535 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2022 | Common stock, par value $0.001 per share | SSaleDisposed | −25,000 | $17.01 | −$425,250 | 736,724 | Direct | |
| Sep 13, 2022 | Common stock, par value $0.001 per share | SSaleDisposed | −7,933 | $17.11 | −$135,733.63 | 728,791 | Direct | |
| Sep 13, 2022 | Common stock, par value $0.001 per share | SSaleDisposed | −75,000 | $16.85 | −$1,263,750 | 653,791 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.